BT7480 targets Nectin-4-expressing tumor cells and then binds to and agonizes CD137 on nearby immune cells to remodel the tumor immune microenvironment, thereby eliminating tumor cells and inhibiting tumor recurrence (115, 116). This evidence concerns the gene TNFRSF9 and neoplasm.